Cargando…

Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period

BACKGROUND: Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine tumor with a short replication time and a rapid growth rate. Prognostic factors for SCLC in clinical practice are scarce. Retrospective analysis of 8‐year extensive‐stage SCLC data from the Department Respiratory and Int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ni, Jun, Zhang, Xiaotong, Wang, Hanping, Si, Xiaoyan, Xu, Yan, Zhao, Jing, Chen, Minjiang, Zhang, Li, Wang, Mengzhao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8841711/ https://www.ncbi.nlm.nih.gov/pubmed/34970848 http://dx.doi.org/10.1111/1759-7714.14289

Ejemplares similares

Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial
por: Ni, Jun, et al.
Publicado: (2023)

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China
por: Miao, Kang, et al.
Publicado: (2022)

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer
por: Miao, Kang, et al.
Publicado: (2022)

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non– small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2022)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
por: Wang, Hanping, et al.
Publicado: (2018)

Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study
por: Jun, Ni, et al.
Publicado: (2020)

Genomic characteristics of driver genes in Chinese patients with non‐small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

The development of a tumor‐associated autoantibodies panel to predict clinical outcomes for immune checkpoint inhibitor‐based treatment in patients with advanced non‐small‐cell lung cancer
por: Zhao, Jing, et al.
Publicado: (2023)

Leptomeningeal enhancement in magnetic resonance imaging predicts poor prognosis in lung adenocarcinoma patients with leptomeningeal metastasis
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Analysis of cytokines in bronchoalveolar lavage fluid in patients with checkpoint inhibitor pneumonitis and pulmonary infection: A case–control study
por: Si, Xiaoyan, et al.
Publicado: (2023)

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum‐pemetrexed: The first report of two cases
por: Si, Xiaoyan, et al.
Publicado: (2020)

Histologic transformation of lung cancer during pembrolizumab therapy: A case report
por: Si, Xiaoyan, et al.
Publicado: (2020)

Abivertinib in patients with T790M‐positive advanced NSCLC and its subsequent treatment with osimertinib
por: Wang, Hanping, et al.
Publicado: (2020)

Opportunistic infections complicating immunotherapy for non‐small cell lung cancer
por: Liu, Ziwei, et al.
Publicado: (2020)

Nimotuzumab combined with chemotherapy as first‐line treatment for advanced lung squamous cell carcinoma
por: Si, Xiaoyan, et al.
Publicado: (2018)

Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non‐small cell lung cancer patients
por: Song, Peng, et al.
Publicado: (2020)

Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer
por: Xu, Yan, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC
por: Zhang, Haoran, et al.
Publicado: (2023)

Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy
por: Tong, Bing, et al.
Publicado: (2017)

Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease
por: Wang, Hanping, et al.
Publicado: (2019)

Prognostic role of circulating tumor cells in patients with EGFR‐mutated or ALK‐rearranged non‐small cell lung cancer
por: Tong, Bing, et al.
Publicado: (2018)

NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score
por: Song, Peng, et al.
Publicado: (2020)

Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death
por: Chen, Minjiang, et al.
Publicado: (2015)

Single‐center study to determine the safety and efficacy of CT‐707 in Chinese patients with advanced anaplastic lymphoma kinase‐rearranged non‐small‐cell lung cancer
por: Song, Peng, et al.
Publicado: (2020)

Clinical characteristics and outcomes of immune checkpoint inhibitor-induced diabetes mellitus
por: Liu, Jia, et al.
Publicado: (2022)

Clinicopathological characteristics of lung cancer in patients with systemic sclerosis
por: Chen, Minjiang, et al.
Publicado: (2020)

Management of anlotinib‐related adverse events in patients with advanced non‐small cell lung cancer: Experiences in ALTER‐0303
por: Si, Xiaoyan, et al.
Publicado: (2019)

The prognostic role of circulating CD8(+) T cell proliferation in patients with untreated extensive stage small cell lung cancer
por: An, Ning, et al.
Publicado: (2019)

Prognostic Factors and Survival Benefits of Antitumor Treatments for Advanced Non-Small Cell Lung Cancer Patients With Central Nervous System Metastasis With or Without Driver Genes: A Chinese Single-Center Cohort Study
por: Gao, Xiaoxing, et al.
Publicado: (2022)

Circulating cytokines associated with clinical outcomes in advanced non‐small cell lung cancer patients who received chemoimmunotherapy
por: Shi, Yuequan, et al.
Publicado: (2021)

A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer
por: Si, Xiaoyan, et al.
Publicado: (2020)

Prognostic impact of maximum standardized uptake value on (18)F‐FDG PET/CT imaging of the primary lung lesion on survival in advanced non‐small cell lung cancer: A retrospective study
por: Qiu, Xiaoling, et al.
Publicado: (2021)

Feasibility and reliability of evaluate PD‐L1 expression determination using small biopsy specimens in non‐small cell lung cancer
por: Chen, Minjiang, et al.
Publicado: (2021)

Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
por: Chen, Minjiang, et al.
Publicado: (2019)

Harness the synergy between targeted therapy and immunotherapy: what have we learned and where are we headed?
por: Liu, Xiaoyan, et al.
Publicado: (2017)

Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib
por: Liang, Hongge, et al.
Publicado: (2019)

Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor‐associated adverse events
por: Song, Peng, et al.
Publicado: (2020)

Pretreatment prognostic nutritional index is a prognostic marker for extensive-stage small cell lung cancer patients treated with anlotinib
por: Liu, Jingjing, et al.
Publicado: (2020)

Study protocol of KeyPemls‐004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non‐small cell lung cancer and progressive disease (PD) after immunotherapy (PD‐1/PD‐L1 inhibitor) alone or in combination with platinum‐doublet chemotherapy
por: Liu, Jia, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_tq7tda2o97lpicn6k7d4qblslp